Pregabalin NDC 72888-049

NDC codes

FDA NDC Directory

Product NDC (as listed)72888-049Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72888-0049Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72888-049-30	72888004930	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (72888-049-30)Marketed from Mar 22, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pregabalin
Generic name (nonproprietary): pregabalin
Active ingredients: Pregabalin — 82.5 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Advagen Pharma Ltd.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215249
Marketing start: Mar 22, 2022
Listing expires: Dec 31, 2027
DEA schedule: CV
Identifiers: Product ID 72888-049_49fe33c0-b2ae-e0c1-e063-6294a90a36a4SPL ID 49fe33c0-b2ae-e0c1-e063-6294a90a36a4SPL set ID 2ffee7e7-bfa0-4933-9baf-7df55080816eRxCUI 1988974, 1988977, 1988980UNII 55JG375S6MUPC 0372888049304, 0372888051307, 0372888050300

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472888004930 followed by a unit qualifier and the quantity

Package 72888-0049-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 4, 2026.

Indications (excerpt from the label)

Pregabalin extended-release tablets are indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy Postherpetic neuralgia Efficacy of pregabalin extended-release tablets has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. Pregabalin extended-release tablets are indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy(DPN) ( 1 ) Postherpetic neuralgia (PHN)( 1 ) Efficacy of pregabalin extended-release tablets has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizur…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215249

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215249
Product	Strength	Form · route	Labeler	Product NDC
Pregabalin	Pregabalin 330 mg/1	Tablet, Film coated, Extended releaseOral	Advagen Pharma Ltd.	72888-051
Pregabalin	Pregabalin 165 mg/1	Tablet, Film coated, Extended releaseOral	Advagen Pharma Ltd.	72888-050